GB9605705D0 — Therapeutic agents
Assigned to Pfizer Ltd Great Britain · Expires 1996-05-22 · 30y expired
What this patent protects
An antifungal compound of formula (I): <CHEM> or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, wherein X is CH or N; R<1> is phenyl subsituted with 1 to 3 substituents each independently selected from halo and C…
USPTO Abstract
An antifungal compound of formula (I): <CHEM> or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, wherein X is CH or N; R<1> is phenyl subsituted with 1 to 3 substituents each independently selected from halo and CF3; R<2> is (hydroxy)C1-C4 alkyl, CONH2, S(O)m(C1-C4 alkyl), Ar or Het; m is 1 or 2; Ar is phenyl optionally monosubstituted with halo or CF3; and Het is a C-linked 6-membered nitrogen-containing aromatic heterocyclic group containing 1 or 2 nitrogen atoms, or a C- or N-linked 5-membered nitrogen-containing aromatic heterocyclic group containing from 2 to 4 nitrogen atoms, wherein either of said heterocyclic groups is optionally substituted with C1-C4 alkyl or (C1-C4 alkoxy)methyl.
Drugs covered by this patent
- Vivjoa (OTESECONAZOLE) · Mycovia Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.